Key facts
- This page summarizes Robert Nelsen's Form 4 filing for Denali Therapeutics Inc. (DNLI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2021, 18:35.
Robert Nelsen - 02 Jun 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)
- Reporting relationship
- Director
- Issuer ticker
- DNLI
- Reported as of
- 02 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2021, 18:35:30 UTC
- Prior SEC filing
- 25 May 2021
- Next SEC filing
- 16 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tyler Nielsen, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Nelsen filed Form 4 for Denali Therapeutics Inc. (DNLI) on 04 Jun 2021.
Change
- Previous filing in this sequence was filed on 25 May 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DNLI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,074
- Change %
- +20%
- Price
- $0.000000
- Shares after
- 12,432
- Date
- 02 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
DNLI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 9,668,749
- Date
- 02 Jun 2021
- Ownership
- Held by ARCH Venture Fund VIII, L.P.
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DNLI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +6,222
- Change %
- Price
- $0.000000
- Shares after
- 6,222
- Date
- 02 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,222
- Exercise price
- $63.76
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Footnote F2
The sole general partner of ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII") is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The Reporting Person is a managing director of ARCH VIII LLC and may be deemed to beneficially own the shares held by ARCH Fund VIII. Mr. Nelsen disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Footnote F3
100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.